Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Future developments in immunotherapy for treatment of biliary tract cancer

Aiwu Ruth He • 5 Jul 2022
ESMO WCGIC 2022
Bile Duct Cancer Antibodies Durvalumab

Aiwu Ruth He, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA, comments on future avenues in research for the diagnosis and treatment of biliary tract cancer. Specifically, Dr He comments on the potential identification of novel biomarkers which may aid in the selection of patients with biliary tract cancer who could benefit from treatment with durvalumab plus chemotherapy. Moreover, personalized therapy and fibroblast growth factor receptor (FGFR) inhibitors for the treatment of biliary tract cancer are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

More from Aiwu Ruth He

Highlights in biliary tract and liver cancers from ESMO WCGIC 2022
1:11
Highlights in biliary tract and liver cancers from ESMO WCGIC 2022
Aiwu Ruth He • 5 Jul 2022
Subgroup analysis of the TOPAZ-1 study by primary tumor location
5:45
Subgroup analysis of the TOPAZ-1 study by primary tumor location
Aiwu Ruth He • 5 Jul 2022

Related Videos

GI highlights at ESMO 2026: Companion-002, EMERALD-3 and HARMONi-GI1
1:22
GI highlights at ESMO 2026: Companion-002, EMERALD-3 and HARMONi-GI1
Hong Jae Chon • 26 Oct 2026
Management of molecularly actionable BTC
1:19
Management of molecularly actionable BTC
James Harding • 25 Oct 2026
BTC highlights: ACTICCA-1, ARTEMIDE and COMPANION-002
1:25
BTC highlights: ACTICCA-1, ARTEMIDE and COMPANION-002
James Harding • 25 Oct 2026
HARMONi-GI1: 1L chemotherapy with durvalumab or ivonescimab for advanced BTC
2:10
HARMONi-GI1: 1L chemotherapy with durvalumab or ivonescimab for advanced BTC
James Harding • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals